The New PSI Pharmaceutical Laboratory Is Ready For Production

The New PSI Pharmaceutical Laboratory Is Ready For Production Paul Scherrer Institut (PSI, ENS Corporate Member) announced that its new pharmaceutical laboratory for the manufacture of radiopharmaceuticals is ready for production, accordingly to the operating licence granted by the Swiss Agency for Therapeutic Products (Swissmedic). For more than 20 years, in collaboration with ETH Zurich,…

nuclear medicine

Framatome Announces New Investment Supporting Nuclear Medicine

Framatome Announces New Investment Supporting Nuclear Medicine Framatome (ENS Corporate Member) announced that it acquired a minority stake in the French startup Global Morpho Pharma. With this investment, Framatome strengthens its activities serving nuclear medicine development and expands its support for the supply chain of Lutetium-177 and other promising isotopes for therapeutic applications. Global Morpho…

Urenco

Urenco Annual Sustainability Report 2021 Is Available Online

Urenco Annual Sustainability Report 2021 Is Available Online Urenco (ENS Corporate Member since June 2022) published online its Annual Sustainability Report 2021 “Delivering for a net zero world”. The company stresses its commitment to a greener and more sustainable future by furthering nuclear energy’s contribution, thanks also to the positive impact on global climate change…

Global Nuclear Community Calls For Immediate IAEA Access To Zaporizhzhya NPP

Global Nuclear Community Calls For Immediate IAEA Access To Zaporizhzhya NPP Representatives of nuclear industry trade associations and professional societies have issued the following statement regarding the Zaporizhzhya Nuclear Power Plant in Ukraine: The International Atomic Energy Agency (IAEA) should be granted immediate, unconditional, and unrestricted access to Zaporizhzhya Nuclear Power Plant to assess the…

nrg

NRG And Curium Sign Contract For Production of Mo-99

NRG And Curium Sign Contract For Production of Mo-99 NRG (ENS Corporate Member) and Curium have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m). Tc-99m is the most used isotope in nuclear medicine for diagnosing life-threatening diseases, such as cardiovascular diseases, lung and brain disorders and cancer. With…